Kalon Stake Gives Fujifilm Ebola Vaccine Capacity

A Fujifilm Holdings Corp. subsidiary is to acquire a major stake in a private U.S. contract vaccine manufacturing firm, expanding the Japanese group's interests in the growing biologics production field and providing it with new capabilities for Ebola vaccines if needed.

Fujifilm Diosynth Biotechnologies U.S.A (FDBU) has signed an interest purchase agreement with the owners of Kalon Biotherapeutics, which at closing in a few months' time will give FDBU initial 49% ownership of the College Station, Texas-based operation, and rights to appoint a majority of its board.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas